Reported Earlier, Medtronic's PulseSelect PFA System Shows 98% Success in Treating Atrial Fibrillation, Study Reveals High Lesion Durability
Portfolio Pulse from Benzinga Newsdesk
Medtronic's PulseSelect PFA System shows a 98% success rate in treating atrial fibrillation, with high lesion durability. The study results were presented at the APHRS meeting, highlighting the system's effectiveness and global expansion.
September 30, 2024 | 7:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medtronic's PulseSelect PFA System demonstrates a 98% success rate in treating atrial fibrillation, with high lesion durability. The system is expanding globally, with regulatory approvals in China, Australia, and Japan.
The high success rate and durability of the PulseSelect PFA System in treating atrial fibrillation are likely to boost Medtronic's reputation and market share in the healthcare technology sector. The global expansion, particularly in the APAC region, indicates strong growth potential and increased revenue opportunities.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100